GlassScriptPhysician profile
Sarah J Evans
NPI 1922358555
$6,202.42
in general payments reported to CMS, 2019-2025
38 companies · $1,874 in 2025
The $1,874 reported for 2025 was more than what 94% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $565 · 2022: $1,014 · 2023: $1,018 · 2024: $1,732 · 2025: $1,874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,379 · Consulting Fee: $150 · Education: $94.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,378.91 |
| Consulting Fee | $150.00 |
| Education | $94.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $563.14 | 2021-2025 | Farxiga, Lokelma |
| Amgen INC. | $557.78 | 2022-2025 | Repatha, Repatha, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $545.99 | 2022-2025 | |
| Opko Pharmaceuticals, LLC | $450.92 | 2022-2025 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $430.63 | 2021-2025 | |
| Travere Therapeutics, INC. | $307.00 | 2024-2025 | |
| Akebia Therapeutics INC | $252.75 | 2022-2025 | Vafseo, Auryxia |
| Janssen Pharmaceuticals, INC | $246.12 | 2021-2024 | Xarelto |
| Kyowa Kirin, INC. | $237.19 | 2023-2025 | Crysvita |
| Ardelyx, INC. | $225.60 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Aurinia Pharma U.S., INC. | $221.96 | 2022-2025 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $210.04 | 2022-2025 | Jynarque |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $197.31 | 2021-2022 | |
| Fresenius USA Marketing, INC. | $194.95 | 2022-2025 | Velphoro |
| Mallinckrodt Hospital Products INC. | $188.86 | 2023-2025 | Terlivaz, Acthar |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.